HBM Healthcare Investments AG successfully completed the placement of the bond early, with Helvetische Bank AG and Raiffeisen Schweiz Cooperative acting as Joint-Lead Managers. Due to the strong demand, the coupon was fixed at the lower end of the indicated coupon range at 1⅛% and HBM Healthcare Investments AG increased the issue amount and exercised the option of reopening to the maximum of CHF 100 million. The subscription period ended prematurely today at 4.00pm.
'We are delighted with the extremely positive response to our bond on the capital market', says Erwin Troxler, CFO of HBM Healthcare Investments AG.
The provisional admission to trading on SIX Swiss Exchange is expected to take place on 9 July 2021 and the settlement on 12 July 2021.
For further information, please contact Erwin Troxler, tel.: +41 41 710 75 77,
About HBM Healthcare Investments
HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).
The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for bonds or any other securities of HBM Healthcare Investments Ltd. This news release does not constitute a prospectus within the meaning of the Swiss Financial Services Act («FinSA») and implementing provisions under the Swiss Financial Services Ordinance («FinSO») nor a listing prospectus in the sense of the Listing Rules of SIX Swiss Exchange Ltd or a prospectus pursuant to any other legislation or regulation. A decision to purchase or subscribe for bonds must be made solely on the basis of the relevant prospectus. The preliminary prospectus and final prospectus both issued in German relating to the bonds (which are expected to be available on 15 June 2021 and 18 June 2021, respectively) may be ordered free of charge by e-mail from Helvetische Bank AG at [email protected] or by calling +41 (0)44 204 56 19.
This news release does not constitute a prospectus or a supplementary prospectus pursuant to the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the «EU Prospectus Regulation») or the EU Prospectus Regulation as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the «UK Prospectus Regulation»). This news release is only addressed to, and is only directed at, qualified investors in any member state of the European Economic Area within the meaning of the EU Prospectus Regulation. The bonds are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area.
This news release is directed only at persons who are qualified investors within the meaning of the UK Prospectus Regulation and who (i) have professional experience in matters relating to investments falling within Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are persons falling within Article 49 (2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or to whom it may otherwise lawfully be communicated (all such persons together being referred to as relevant persons). The bonds are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom. This news release is only directed at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons.
NEITHER THIS DOCUMENT NOR ANY PART OR COPY OF IT NOR THE INFORMATION CONTAINED IN IT AND ANY RELATED MATERIALS MAY BE TAKEN OR TRANSMITTED INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR TO ANY RETAIL INVESTOR IN THE EEA OR THE UNITED KINGDOM OR DISTRIBUTED OR REDISTRIBUTED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, TO ANY RETAIL INVESTOR IN THE EEA OR THE UNITED KINGDOM OR TO ANY RESIDENT THEREOF.This news release is not for distribution in, nor does it constitute an offer of securities in the United States. Neither this news release nor any copy of it may be taken or transmitted into the United States, its territories or possessions, or distributed, directly or indirectly, in the United States, its territories or possessions or to any US person as defined in Regulation S («Regulation S») under the US Securities Act 1933, as amended (the «Securities Act»). Any failure to comply with this restriction may constitute a violation of United States securities law. Accordingly, each person viewing this document will be deemed to have represented that it is not a US person within the meaning of Regulation S of the Securities Act. Securities may not be offered or sold in the United States absent registration or an exemption from registration. HBM Healthcare Investments Ltd has not registered and does not intend to register any securities that may be described herein in the United States or to conduct a public offering of any securities in the United States.
This document is not an offer of securities for sale or purchase in the United States. The securities to which this document relates have not been and will not be registered under the Securities Act, and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will not be a public offering of securities in the United States.
This document has been prepared by HBM Healthcare Investments Ltd and may not be copied, amended, offered, sold or otherwise given to third parties by the recipient without the consent of HBM Healthcare Investments Ltd. The German version of the document is applicable and binding in any event. Versions of the document in other languages are for information purposes only. Due care has been taken to ensure that the facts set out herein are accurate and that all opinions expressed herein are fair and reasonable. Some information quoted was obtained from external sources HBM Healthcare Investments Ltd considers to be reliable.HBM Healthcare Investments Ltd cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions. The facts and information set out in this document are as current as possible but may change in the future. Both HBM Healthcare Investments Ltd as such and its directors, officers, employees and advisors or any other person disclaim any express or implied liability or warranty as to the accuracy or completeness of the information contained in this document.
This document may contain projections or other forward-looking statements relating to HBM Healthcare Investments Ltd that involve inherent risks and uncertainties, both general and specific, and there is a risk that the projections, forecasts, plans and other explicit or implicit contents of forward-looking statements may prove to be inaccurate. All forward-looking statements are based on information available to HBM Healthcare Investments Ltd on the date of their publication; HBM Healthcare Investments Ltd is only obliged to update these statements if required to do so by applicable laws.